Moors & Cabot Inc. cut its stake in shares of Danaher Co. (NYSE:DHR) by 7.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,196 shares of the conglomerate’s stock after selling 814 shares during the period. Moors & Cabot Inc.’s holdings in Danaher were worth $870,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Hamilton Point Investment Advisors LLC grew its stake in shares of Danaher by 2.0% in the first quarter. Hamilton Point Investment Advisors LLC now owns 38,188 shares of the conglomerate’s stock worth $3,266,000 after purchasing an additional 735 shares during the last quarter. KCG Holdings Inc. grew its stake in shares of Danaher by 88.3% in the first quarter. KCG Holdings Inc. now owns 14,483 shares of the conglomerate’s stock worth $1,239,000 after purchasing an additional 6,793 shares during the last quarter. National Asset Management Inc. grew its stake in shares of Danaher by 33.7% in the first quarter. National Asset Management Inc. now owns 3,753 shares of the conglomerate’s stock worth $321,000 after purchasing an additional 947 shares during the last quarter. Edgestream Partners L.P. bought a new stake in shares of Danaher in the first quarter worth $465,000. Finally, Fiduciary Trust Co. grew its stake in shares of Danaher by 1.1% in the first quarter. Fiduciary Trust Co. now owns 11,756 shares of the conglomerate’s stock worth $1,005,000 after purchasing an additional 123 shares during the last quarter. Institutional investors own 76.32% of the company’s stock.

Danaher Co. (DHR) traded down $1.30 during mid-day trading on Friday, hitting $92.85. 2,869,800 shares of the stock were exchanged, compared to its average volume of 2,616,866. The company has a market cap of $65,491.23, a PE ratio of 24.20, a PEG ratio of 2.24 and a beta of 1.02. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. Danaher Co. has a one year low of $77.66 and a one year high of $94.82.

Danaher (NYSE:DHR) last released its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.05. The company had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The business’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.87 EPS. research analysts forecast that Danaher Co. will post 3.99 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be given a dividend of $0.14 per share. The ex-dividend date is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.60%. Danaher’s dividend payout ratio (DPR) is presently 16.52%.

In related news, SVP Daniel Raskas sold 37,870 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total value of $3,534,407.10. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total transaction of $11,671,620.96. Following the completion of the sale, the chief executive officer now owns 271,737 shares in the company, valued at approximately $25,173,715.68. The disclosure for this sale can be found here. Insiders have sold a total of 273,810 shares of company stock worth $25,218,813 in the last three months. Insiders own 12.20% of the company’s stock.

Several analysts recently weighed in on DHR shares. J P Morgan Chase & Co reissued an “overweight” rating and issued a $95.00 price objective on shares of Danaher in a research note on Friday, September 8th. Zacks Investment Research raised shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a research report on Thursday, October 5th. Morgan Stanley reaffirmed an “overweight” rating and set a $95.00 price target (up previously from $86.00) on shares of Danaher in a research report on Friday, October 6th. Cowen reaffirmed a “buy” rating and set a $90.00 price target on shares of Danaher in a research report on Wednesday, October 4th. Finally, Credit Suisse Group upped their price target on shares of Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Danaher currently has an average rating of “Buy” and a consensus price target of $94.05.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/15/danaher-co-dhr-shares-sold-by-moors-cabot-inc.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Stock Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related stocks with our FREE daily email newsletter.